Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 146 articles: HTML format

Single Articles

October 2025
1. TEUNISSEN FR, Oprea-Lager DE, Peters SMB, Smeenk RJ, et al
   Current Developments in Combining External-Beam Radiotherapy and (177)Lu-Labeled PSMA Ligands for Prostate Cancer Treatment.
   J Nucl Med. 2025 Oct 3:jnumed.125.270465. doi: 10.2967/jnumed.125.270465.
   PubMed     Abstract available
   
   
   
2. SARTOR O, Emmett L, Herrmann K
   Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer.
   J Nucl Med. 2025 Oct 3:jnumed.125.271144. doi: 10.2967/jnumed.125.271144.
   PubMed    
   
   
   
3. KUCUK NO, Coskun N, Araz M, Alan Selcuk N, et al
   Initial Multicenter Experience with [(161)Tb]Tb-PSMA in [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results.
   J Nucl Med. 2025 Oct 3:jnumed.125.270952. doi: 10.2967/jnumed.125.270952.
   PubMed     Abstract available
   
   
   
4. KARMANN A, Rose S, Herrmann K, Kratochwil C, et al
   alpha-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer.
   J Nucl Med. 2025 Oct 3:jnumed.125.270940. doi: 10.2967/jnumed.125.270940.
   PubMed    
   
   
   
5. HOYVIK AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, et al
   Optimizing [(212)Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts.
   J Nucl Med. 2025 Oct 3:jnumed.125.270444. doi: 10.2967/jnumed.125.270444.
   PubMed     Abstract available
   
   
   
6. 
   Biomarkers in Prostate Cancer: What's in the Blood?
   J Nucl Med. 2025;66:6A.
   PubMed    
   
   
   September 2025
7. LIU F, Monterosso ME, Boucher D, Shakti S, et al
   Preclinical Evaluation of [(212)Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen-Targeted alpha-Therapy for Prostate Cancer.
   J Nucl Med. 2025 Sep 25:jnumed.125.269707. doi: 10.2967/jnumed.125.269707.
   PubMed     Abstract available
   
   
   
8. HADASCHIK B, Gillessen S, Sartor O
   (177)Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer.
   J Nucl Med. 2025 Sep 25:jnumed.125.270836. doi: 10.2967/jnumed.125.270836.
   PubMed    
   
   
   
9. GIRI VK, Kolodny GM, Garnick MB
   First-Line [(177)Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
   J Nucl Med. 2025 Sep 25:jnumed.125.270704. doi: 10.2967/jnumed.125.270704.
   PubMed     Abstract available
   
   
   
10. PEPIN A, Doucette A, Vapiwala N, Narayan VK, et al
    Safety of the Combination of External Beam Radiotherapy with (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270316. doi: 10.2967/jnumed.125.270316.
    PubMed     Abstract available
    
    
    
11. BEINTNER-SKAWRAN S, Gafita A, Lorenzini T, Tauber R, et al
    [(68)Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.
    J Nucl Med. 2025 Sep 11:jnumed.125.269584. doi: 10.2967/jnumed.125.269584.
    PubMed     Abstract available
    
    
    August 2025
12. HOLZGREVE A, Delker A, Ells Z, Brosch-Lenz J, et al
    Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of (177)Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol.
    J Nucl Med. 2025 Aug 28:jnumed.125.269495. doi: 10.2967/jnumed.125.269495.
    PubMed     Abstract available
    
    
    
13. ALTUNAY B, Schafer L, Morgenroth A, Pena Q, et al
    Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy.
    J Nucl Med. 2025 Aug 28:jnumed.125.270317. doi: 10.2967/jnumed.125.270317.
    PubMed     Abstract available
    
    
    
14. GRKOVSKI M, Krebs SS, O'Donoghue JA, Kuten J, et al
    Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Aug 7:jnumed.125.270170. doi: 10.2967/jnumed.125.270170.
    PubMed     Abstract available
    
    
    July 2025
15. DENIS CS, Cousin F, De Laere B, Vanwelkenhuyzen J, et al
    Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Jul 31:jnumed.125.269729. doi: 10.2967/jnumed.125.269729.
    PubMed     Abstract available
    
    
    
16. CHEN Y, Zhang X, Wang X, Liu Y, et al
    Interspecies Variability in Biodistribution and PET Imaging Performance of [(18)F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer.
    J Nucl Med. 2025 Jul 17:jnumed.125.270069. doi: 10.2967/jnumed.125.270069.
    PubMed     Abstract available
    
    
    
17. KOHAN A, Metser U, Luke W, Rashid M, et al
    A Prospective Provincial Registry of (18)F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men.
    J Nucl Med. 2025 Jul 3:jnumed.125.269653. doi: 10.2967/jnumed.125.269653.
    PubMed     Abstract available
    
    
    
18. KASHYAP R, Buteau JP, Bressel M, Eifer M, et al
    Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.
    J Nucl Med. 2025 Jul 3:jnumed.125.269640. doi: 10.2967/jnumed.125.269640.
    PubMed     Abstract available
    
    
    June 2025
19. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country.
    J Nucl Med. 2025 Jun 12:jnumed.125.269996. doi: 10.2967/jnumed.125.269996.
    PubMed     Abstract available
    
    
    
20. BOBBA KN, Wadhwa A, Bidkar AP, Raveendran A, et al
    Evaluation of (134)Ce/(134)La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.
    J Nucl Med. 2025 Jun 12:jnumed.125.269751. doi: 10.2967/jnumed.125.269751.
    PubMed     Abstract available
    
    
    
21. SCHMITL S, Kretschmer-Chott E, Patronas EM, Kramer G, et al
    Efficacy, Safety, Blood Kinetics, and (213)Bi Distribution Studies of [(225)Ac]Ac-SibuDAB in Prostate Cancer Patients.
    J Nucl Med. 2025 Jun 5:jnumed.125.269655. doi: 10.2967/jnumed.125.269655.
    PubMed     Abstract available
    
    
    
22. FANTI S, Robles Barba JJ, Behr S, Maurer T, et al
    Imaging Efficacy of [(18)F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269266. doi: 10.2967/jnumed.124.269266.
    PubMed     Abstract available
    
    
    
23. GAFITA A, Schroeder JA, Ceci F, Oldan JD, et al
    Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
    J Nucl Med. 2025 Jun 5:jnumed.124.268071. doi: 10.2967/jnumed.124.268071.
    PubMed     Abstract available
    
    
    
24. IAGARU A, Suarez JF, Behr S, Aggarwal R, et al
    Imaging Efficacy of [(18)F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269007. doi: 10.2967/jnumed.124.269007.
    PubMed     Abstract available
    
    
    May 2025
25. VAN RIEL JHHM, Donswijk ML, Brouwer C, Gerritsen WR, et al
    Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with (223)Ra Therapy in Daily Practice.
    J Nucl Med. 2025 May 22:jnumed.125.269746. doi: 10.2967/jnumed.125.269746.
    PubMed     Abstract available
    
    
    
26. SATAPATHY S, Das CK, Goyal S, Sood A, et al
    (177)Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial.
    J Nucl Med. 2025 May 22:jnumed.125.269913. doi: 10.2967/jnumed.125.269913.
    PubMed     Abstract available
    
    
    April 2025
27. HARSINI S, Soleimani M, Wilson D, Uribe C, et al
    A Phase I/II Study of [(177)Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol.
    J Nucl Med. 2025 Apr 30:jnumed.124.269064. doi: 10.2967/jnumed.124.269064.
    PubMed     Abstract available
    
    
    
28. UNTERRAINER LM, De Leiris N, Unterrainer M, Delker A, et al
    Evidence-Based Clinical Protocols to Monitor Efficacy of [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
    J Nucl Med. 2025 Apr 24:jnumed.124.269431. doi: 10.2967/jnumed.124.269431.
    PubMed     Abstract available
    
    
    
29. DE OLIVEIRA TAVEIRA M, Razmaria AA, Schoder H, Yeh R, et al
    Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT.
    J Nucl Med. 2025 Apr 10:jnumed.124.269361. doi: 10.2967/jnumed.124.269361.
    PubMed     Abstract available
    
    
    March 2025
30. CHEN DC, Buteau JP, Emmett L, Alipour R, et al
    Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [(68)Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
    J Nucl Med. 2025 Mar 27:jnumed.124.268901. doi: 10.2967/jnumed.124.268901.
    PubMed     Abstract available
    
    
    
31. YANG H, Wang J, Wen X, Guo H, et al
    Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives (68)Ga/(177)Lu-LNC1011 as Prostate Cancer Theranostics.
    J Nucl Med. 2025 Mar 20:jnumed.124.268959. doi: 10.2967/jnumed.124.268959.
    PubMed     Abstract available
    
    
    
32. TANG W, Qi L, Chen M, Zhang Y, et al
    Additive Value of [(68)Ga]Ga-RM26 PET/CT to [(68)Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study.
    J Nucl Med. 2025 Mar 20:jnumed.124.269189. doi: 10.2967/jnumed.124.269189.
    PubMed     Abstract available
    
    
    
33. BERNER K, Hernes E, Kvassheim M, Revheim ME, et al
    First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Mar 13:jnumed.124.269299. doi: 10.2967/jnumed.124.269299.
    PubMed     Abstract available
    
    
    
34. JEWELL KE, Buteau JP, Medhurst E, Kwan EM, et al
    Safety and Efficacy of 20 Cycles of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Mar 13:jnumed.124.269447. doi: 10.2967/jnumed.124.269447.
    PubMed    
    
    
    
35. FOXTON C, Waldron B, Veggerby Gronlund R, Simon JJ, et al
    Preclinical Evaluation of (177)Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268508. doi: 10.2967/jnumed.124.268508.
    PubMed     Abstract available
    
    
    
36. JOHNSTONE CN, Osellame LD, Cao Z, McDonald AF, et al
    DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of (177)Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
    J Nucl Med. 2025;66:385-390.
    PubMed     Abstract available
    
    
    February 2025
37. TURCO F, Gillessen S, Herrmann K, Paone G, et al
    Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.267730. doi: 10.2967/jnumed.124.267730.
    PubMed     Abstract available
    
    
    
38. MURTHY V, Ludwig V, Gafita A, Hope TA, et al
    The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268818. doi: 10.2967/jnumed.124.268818.
    PubMed     Abstract available
    
    
    
39. EIFER M, Sutherland DEK, Goncalves I, Buteau JP, et al
    Therapy-Related Myeloid Neoplasms After [(177)Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.
    J Nucl Med. 2025 Feb 20:jnumed.124.268640. doi: 10.2967/jnumed.124.268640.
    PubMed     Abstract available
    
    
    
40. KOSTOS L, Buteau JP, Kong G, Tran B, et al
    Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.269252. doi: 10.2967/jnumed.124.269252.
    PubMed     Abstract available
    
    
    
41. LINDENBERG L, Hope TA, Lin FI, Rowe SP, et al
    Safety, Dosimetry, and Feasibility of [(68)Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.268318. doi: 10.2967/jnumed.124.268318.
    PubMed     Abstract available
    
    
    
42. DERLIN T, Widjaja L, Harke NN, Czerner C, et al
    (99m)Tc-MIP-1404 SPECT/CT Companion Diagnostic for (177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.269319. doi: 10.2967/jnumed.124.269319.
    PubMed     Abstract available
    
    
    
43. VAN DER GAAG S, Vis AN, Bartelink IH, Koppes JCC, et al
    Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET.
    J Nucl Med. 2025 Feb 6:jnumed.124.268340. doi: 10.2967/jnumed.124.268340.
    PubMed     Abstract available
    
    
    
44. MORAITIS A, Kahl T, Kandziora J, Jentzen W, et al
    Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy.
    J Nucl Med. 2025 Feb 6:jnumed.124.268719. doi: 10.2967/jnumed.124.268719.
    PubMed     Abstract available
    
    
    January 2025
45. LAWAL IO, Mushtaq A, Jani AB, Rupji M, et al
    Diuresis During (18)F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
    J Nucl Med. 2025 Jan 23:jnumed.124.268574. doi: 10.2967/jnumed.124.268574.
    PubMed     Abstract available
    
    
    
46. MADSEN C, Fuglo D, Pedersen M, Broholm R, et al
    Prospective Head-to-Head Comparison of (18)F-PSMA PET/CT and (18)F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer.
    J Nucl Med. 2025 Jan 8:jnumed.124.268275. doi: 10.2967/jnumed.124.268275.
    PubMed     Abstract available
    
    
    
47. MILLER SR, Gonzalez RT, Jackson WC, Caram MEV, et al
    Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System.
    J Nucl Med. 2025;66:75-83.
    PubMed     Abstract available
    
    
    
48. UNTERRAINER LM, Hope TA, Fendler WP, Grogan T, et al
    Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
    J Nucl Med. 2025;66:54-60.
    PubMed     Abstract available
    
    
    
49. ZAID NRR, Bastiaannet R, Hobbs R, Sgouros G, et al
    Mathematic Modeling of Tumor Growth During [(177)Lu]Lu-PSMA Therapy: Insights into Treatment Optimization.
    J Nucl Med. 2025;66:84-90.
    PubMed     Abstract available
    
    
    
50. SCHWEIGER L, Maurer T, Simon R, Horn T, et al
    Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery.
    J Nucl Med. 2025;66:67-72.
    PubMed     Abstract available
    
    
    November 2024
51. DEMIRCI RA, Ghodsi A, Gulati R, Behnia S, et al
    PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617: Importance of (18)F-FDG-Avid Discordant Findings.
    J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167.
    PubMed     Abstract available
    
    
    
52. WENZEL M, Koll F, Hoeh B, Humke C, et al
    Real-World Comparison of Cabazitaxel Versus (177)Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Nov 14:jnumed.124.268807. doi: 10.2967/jnumed.124.268807.
    PubMed     Abstract available
    
    
    
53. DEMIRCI RA, Gulati R, Hawley JE, Yezefski T, et al
    SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
    J Nucl Med. 2024 Nov 7:jnumed.124.267665. doi: 10.2967/jnumed.124.267665.
    PubMed     Abstract available
    
    
    
54. ZAGNI F, Vetrone L, Farolfi A, Vadala M, et al
    Feasibility of (177)Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer.
    J Nucl Med. 2024 Nov 7:jnumed.124.268062. doi: 10.2967/jnumed.124.268062.
    PubMed    
    
    
    
55. SAIDI A, Stallons TA, Wong AG, Torgue JJ, et al
    Preclinical Investigation of [(212)Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model.
    J Nucl Med. 2024;65:1769-1775.
    PubMed     Abstract available
    
    
    October 2024
56. SONNI I, Weiner AB, Doddipalli S, Deol M, et al
    Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.
    J Nucl Med. 2024 Oct 30:jnumed.124.268443. doi: 10.2967/jnumed.124.268443.
    PubMed     Abstract available
    
    
    
57. HUANG RR, Zuo C, Mona CE, Holzgreve A, et al
    FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
    J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037.
    PubMed     Abstract available
    
    
    
58. SWIHA M, Pathmanandavel S, Papa N, Sabahi Z, et al
    Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.267606. doi: 10.2967/jnumed.124.267606.
    PubMed     Abstract available
    
    
    
59. MUNIZ M, Sartor O, Orme JJ, Koch RM, et al
    Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2024 Oct 30:jnumed.124.268277. doi: 10.2967/jnumed.124.268277.
    PubMed     Abstract available
    
    
    
60. PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al
    Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
    J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256.
    PubMed    
    
    
    
61. CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al
    Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363.
    PubMed     Abstract available
    
    
    September 2024
62. MURTHY V, Voter AF, Nguyen K, Allen-Auerbach M, et al
    Efficacy and Toxicity of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
    J Nucl Med. 2024 Sep 26:jnumed.124.267816. doi: 10.2967/jnumed.124.267816.
    PubMed     Abstract available
    
    
    
63. BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al
    Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877.
    PubMed     Abstract available
    
    
    
64. POULIOT F, Saad F, Rousseau E, Richard PO, et al
    Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020.
    PubMed     Abstract available
    
    
    
65. GAFITA A, Voter A, Shesadri S, Spitz A, et al
    Initial Experience with [(177)Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
    J Nucl Med. 2024 Sep 19:jnumed.124.267723. doi: 10.2967/jnumed.124.267723.
    PubMed     Abstract available
    
    
    
66. BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al
    Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
    J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751.
    PubMed     Abstract available
    
    
    
67. POSCHENRIEDER A, Taleska J, Schaetz L
    (177)Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?
    J Nucl Med. 2024;65:1340-1342.
    PubMed    
    
    
    
68. BELGE BILGIN G, Burkett BJ, Bilgin C, Orme JJ, et al
    Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience.
    J Nucl Med. 2024;65:1402-1408.
    PubMed     Abstract available
    
    
    August 2024
69. WONG AJN, Ko HS, Hofman MS
    Navigating the Future of Prostate Cancer Care: AI-Driven Imaging and Theranostics Through the Lens of RELAINCE.
    J Nucl Med. 2024 Aug 29:jnumed.124.267924. doi: 10.2967/jnumed.124.267924.
    PubMed    
    
    
    
70. THIN P, Hotta M, Gafita A, Grogan T, et al
    Clinical Factors That Influence Repeat (68)Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative (68)Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
    J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591.
    PubMed     Abstract available
    
    
    
71. HO KV, Tatum DS, Watkinson L, Carmack T, et al
    Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
    J Nucl Med. 2024 Aug 14:jnumed.124.267667. doi: 10.2967/jnumed.124.267667.
    PubMed     Abstract available
    
    
    
72. MAINTA IC, Neroladaki A, Wolf NB, Benamran D, et al
    [(68)Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria.
    J Nucl Med. 2024 Aug 8:jnumed.124.267899. doi: 10.2967/jnumed.124.267899.
    PubMed     Abstract available
    
    
    
73. YADAV S, Lowery B, Tuchayi AM, Jiang F, et al
    Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955.
    PubMed     Abstract available
    
    
    
74. OSMAN MM, Iravani A, Mitchell C, Hicks RJ, et al
    (18)F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology.
    J Nucl Med. 2024 Aug 1:jnumed.124.267772. doi: 10.2967/jnumed.124.267772.
    PubMed     Abstract available
    
    
    
75. LI S, Nguyen A, Counter W, John NC, et al
    Utility of (64)Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11 PET/CT.
    J Nucl Med. 2024 Aug 1:jnumed.124.267881. doi: 10.2967/jnumed.124.267881.
    PubMed     Abstract available
    
    
    
76. NIKITAS J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, et al
    Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922.
    PubMed     Abstract available
    
    
    
77. ANGAPPULIGE DH, Barashi NS, Pickersgill N, Weimholt C, et al
    Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.
    J Nucl Med. 2024;65:1210-1216.
    PubMed     Abstract available
    
    
    July 2024
78. DUIN JJ, de Barros HA, van Leeuwen PJ, van der Poel HG, et al
    Reply: Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
    J Nucl Med. 2024 Jul 25:jnumed.124.267658. doi: 10.2967/jnumed.124.267658.
    PubMed    
    
    
    
79. AH-THIANE L, Ferrer L, Supiot S, Rousseau C, et al
    Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
    J Nucl Med. 2024 Jul 25:jnumed.124.267477. doi: 10.2967/jnumed.124.267477.
    PubMed    
    
    
    
80. BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al
    (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
    J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126.
    PubMed     Abstract available
    
    
    
81. BUTEAU JP, Kostos L, Alipour R, Jackson P, et al
    Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [(161)Tb]Tb-PSMA-I&T.
    J Nucl Med. 2024 Jul 11:jnumed.124.267650. doi: 10.2967/jnumed.124.267650.
    PubMed     Abstract available
    
    
    
82. ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al
    Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
    J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452.
    PubMed     Abstract available
    
    
    
83. RATHKE H, Winter E, Bruchertseifer F, Rohrich M, et al
    Deescalated (225)Ac-PSMA-617 Versus (177)Lu/(225)Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients.
    J Nucl Med. 2024;65:1057-1063.
    PubMed     Abstract available
    
    
    June 2024
84. BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al
    Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
    J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586.
    PubMed     Abstract available
    
    
    
85. KUO PH, Esposito G, Ulaner GA, Yoo D, et al
    Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies.
    J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306.
    PubMed     Abstract available
    
    
    
86. EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al
    A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355.
    PubMed     Abstract available
    
    
    
87. PHAM TT, Hungnes IN, Rivas C, Cleaver J, et al
    Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of (99m)Tc and (188)Re Theranostic Agents for Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.124.267450. doi: 10.2967/jnumed.124.267450.
    PubMed     Abstract available
    
    
    
88. SEIFERT R, Telli T, Lapa C, Desaulniers M, et al
    Safety and Efficacy of Extended Therapy with [(177)Lu]Lu-PSMA: A German Multicenter Study.
    J Nucl Med. 2024;65:909-916.
    PubMed     Abstract available
    
    
    May 2024
89. PANDIT-TASKAR N, O'Donoghue JA, Chetty D, Max S, et al
    A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.124.267416. doi: 10.2967/jnumed.124.267416.
    PubMed     Abstract available
    
    
    
90. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
    PubMed     Abstract available
    
    
    
91. FLEMING MT, Hermsen R, Purysko AS, Chau A, et al
    True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
    J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271.
    PubMed     Abstract available
    
    
    
92. ZANG J, Yang Y, Chen S, Wang C, et al
    Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
    J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940.
    PubMed     Abstract available
    
    
    
93. YADAV S, Jiang F, Kurkowska S, Saelee R, et al
    Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
    J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208.
    PubMed     Abstract available
    
    
    
94. MORADI TUCHAYI A, Yadav S, Jiang F, Kim ST, et al
    Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
    J Nucl Med. 2024;65:735-739.
    PubMed     Abstract available
    
    
    April 2024
95. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
    Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
    J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
    PubMed     Abstract available
    
    
    
96. DUAN H, Song H, Davidzon GA, Moradi F, et al
    Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
    PubMed     Abstract available
    
    
    
97. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
    RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
    PubMed     Abstract available
    
    
    
98. HUANG YY, Lin TC, Yang SH, Lai LS, et al
    [(177)Lu]Lu-Prostate-Specific Membrane Antigen-617 in a Patient with Metastatic Castration-Resistant Prostate Cancer and Status After Bilateral Nephrectomy.
    J Nucl Med. 2024 Apr 18:jnumed.124.267533. doi: 10.2967/jnumed.124.267533.
    PubMed    
    
    
    
99. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
    Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
    J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
    PubMed     Abstract available
    
    
    
100. VISCUSE P, Devitt M, Dreicer R
     Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
     J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
     PubMed     Abstract available
     
     
     
101. BAUCKNEHT M, Fornarini G, Di Raimondo T, Pardini M, et al
     Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer.
     J Nucl Med. 2024 Apr 11:jnumed.124.267526. doi: 10.2967/jnumed.124.267526.
     PubMed    
     
     
     
102. HARDIANSYAH D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, et al
     Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [(177)Lu]Lu-PSMA-617 Therapy.
     J Nucl Med. 2024;65:566-572.
     PubMed     Abstract available
     
     
     March 2024
103. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
     Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
     J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
     PubMed     Abstract available
     
     
     
104. SHI J, Li D, Chen M, Fu Y, et al
     The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
     J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
     PubMed     Abstract available
     
     
     
105. HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al
     Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
     J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702.
     PubMed     Abstract available
     
     
     February 2024
106. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
     Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
     J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
     PubMed     Abstract available
     
     
     
107. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
     First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
     PubMed    
     
     
     
108. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
     The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
     J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
     PubMed     Abstract available
     
     
     
109. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
     Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
     J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
     PubMed     Abstract available
     
     
     
110. MAURER T, Thomas C, Hadaschik B
     The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?
     J Nucl Med. 2024 Feb 15:jnumed.123.267187. doi: 10.2967/jnumed.123.267187.
     PubMed    
     
     
     
111. KUMAR S, Crumbaker M, Emmett L
     Reply: Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
     J Nucl Med. 2024;65:333-334.
     PubMed    
     
     
     
112. ASKARI E, Harsini S
     Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
     J Nucl Med. 2024;65:332-333.
     PubMed    
     
     
     January 2024
113. LIGHT A, Lazic S, Houghton K, Bayne M, et al
     Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
     J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
     PubMed     Abstract available
     
     
     
114. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
     Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
     J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
     PubMed     Abstract available
     
     
     
115. RAHBAR K, Boegemann M
     The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
     J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
     PubMed    
     
     
     
116. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
     PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
     J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
     PubMed    
     
     
     
117. RAVI KUMAR AS, Hofman MS
     Unraveling the Impact of (177)Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation.
     J Nucl Med. 2024;65:85-86.
     PubMed    
     
     
     
118. STEINHELFER L, Lunger L, Cala L, Pfob CH, et al
     Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy.
     J Nucl Med. 2024;65:79-84.
     PubMed     Abstract available
     
     
     December 2023
119. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
     First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
     J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
     PubMed     Abstract available
     
     
     
120. BENABDALLAH N, Lu P, Abou DS, Zhang H, et al
     Beyond Average: alpha-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer.
     J Nucl Med. 2023 Dec 14:jnumed.123.266571. doi: 10.2967/jnumed.123.266571.
     PubMed     Abstract available
     
     
     
121. JADVAR H
     Sequential and Combination Therapies of (223)RaCl(2) and Prostate-Specific Membrane Antigen Radioligand Therapy.
     J Nucl Med. 2023;64:1932-1933.
     PubMed    
     
     
     November 2023
122. EMMETT L, Papa N, Counter W, Calais J, et al
     Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
     J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164.
     PubMed     Abstract available
     
     
     
123. WANG F, Liu C, Vidal I, Mana-Ay M, et al
     Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT.
     J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005.
     PubMed     Abstract available
     
     
     
124. KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al
     Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
     J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158.
     PubMed     Abstract available
     
     
     
125. HERRMANN K, Rahbar K, Eiber M, Sparks R, et al
     Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
     J Nucl Med. 2023 Nov 30:jnumed.123.265448. doi: 10.2967/jnumed.123.265448.
     PubMed     Abstract available
     
     
     
126. SARTOR O, Ledet E, Huang M, Schwartz J, et al
     Prediction of Resistance to (177)Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.
     J Nucl Med. 2023;64:1721-1725.
     PubMed     Abstract available
     
     
     October 2023
127. RAHBAR K, Essler M, Eiber M, la Fougere C, et al
     (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study).
     J Nucl Med. 2023 Oct 12:jnumed.123.266125. doi: 10.2967/jnumed.123.266125.
     PubMed     Abstract available
     
     
     
128. MEYER C, Stuparu A, Lueckerath K, Calais J, et al
     Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer.
     J Nucl Med. 2023 Oct 5:jnumed.123.265433. doi: 10.2967/jnumed.123.265433.
     PubMed     Abstract available
     
     
     
129. TSCHAN VJ, Busslinger SD, Bernhardt P, Grundler PV, et al
     Albumin-Binding and Conventional PSMA Ligands in Combination with (161)Tb: Biodistribution, Dosimetry, and Preclinical Therapy.
     J Nucl Med. 2023;64:1625-1631.
     PubMed     Abstract available
     
     
     
130. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
     Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
     J Nucl Med. 2023;64:1632-1637.
     PubMed     Abstract available
     
     
     
131. GRAVES SA
     Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [(177)Lu]Lu-PSMA-617.
     J Nucl Med. 2023;64:1567-1569.
     PubMed     Abstract available
     
     
     September 2023
132. SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al
     PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
     J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
     PubMed     Abstract available
     
     
     
133. RINSCHEID A, Gable A, Wienand G, Pfob C, et al
     An Intrapatient Dosimetry Comparison of (177)Lu-rhPSMA-10.1 and (177)Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2023 Sep 28:jnumed.123.265970. doi: 10.2967/jnumed.123.265970.
     PubMed     Abstract available
     
     
     
134. KLUGE K, Haberl D, Einspieler H, Rasul S, et al
     Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
     J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980.
     PubMed     Abstract available
     
     
     
135. SATAPATHY S, Mittal BR, Sood A, Das CK, et al
     [(177)Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial.
     J Nucl Med. 2023 Sep 14:jnumed.123.266141. doi: 10.2967/jnumed.123.266141.
     PubMed     Abstract available
     
     
     
136. KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al
     Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
     J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878.
     PubMed     Abstract available
     
     
     
137. MURTHY V, Gafita A, Thin P, Nguyen K, et al
     Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with (177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
     J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155.
     PubMed     Abstract available
     
     
     
138. KUMAR S, Crumbaker M, Harvey C, Pathmanandavel S, et al
     The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
     J Nucl Med. 2023;64:1412-1416.
     PubMed     Abstract available
     
     
     
139. MURTHY V, Allen-Auerbach M, Lam R, Owen D, et al
     PSMA-Negative Lesion Progression Under (177)Lu-PSMA Radioligand Therapy.
     J Nucl Med. 2023;64:1502-1503.
     PubMed    
     
     
     
140. HOPE TA, Antonarakis ES, Bodei L, Calais J, et al
     SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-PSMA-617 Radionuclide Therapy.
     J Nucl Med. 2023;64:1417-1423.
     PubMed    
     
     
     August 2023
141. VAN LITH SAM, Pruis IJ, Tolboom N, Snijders TJ, et al
     PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.
     J Nucl Med. 2023 Aug 31:jnumed.123.265738. doi: 10.2967/jnumed.123.265738.
     PubMed     Abstract available
     
     
     
142. HOHBERG M, Reifegerst M, Drzezga A, Wild M, et al
     Prediction of Response to (177)Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC.
     J Nucl Med. 2023 Aug 31:jnumed.122.264953. doi: 10.2967/jnumed.122.264953.
     PubMed     Abstract available
     
     
     
143. HOPE TA, Benz M, Jiang F, Thompson D, et al
     Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.
     J Nucl Med. 2023 Aug 17:jnumed.123.265916. doi: 10.2967/jnumed.123.265916.
     PubMed     Abstract available
     
     
     July 2023
144. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
     Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
     J Nucl Med. 2023 Jul 27:jnumed.123.265523. doi: 10.2967/jnumed.123.265523.
     PubMed     Abstract available
     
     
     
145. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
     Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
     J Nucl Med. 2023 Jul 20:jnumed.123.265771. doi: 10.2967/jnumed.123.265771.
     PubMed     Abstract available
     
     
     
146. STRAUB M, Kupferschlager J, Serna Higuita LM, Weissinger M, et al
     Dual-Time-Point Posttherapy (177)Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.
     J Nucl Med. 2023 Jul 6:jnumed.122.264770. doi: 10.2967/jnumed.122.264770.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.